Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4CNS 4

Conditions

Carcinoma, Hepatocellular 66Carcinoma, Renal Cell 38Liver Neoplasms 20Neoplasm Metastasis 17Carcinoma, Non-Small-Cell Lung 16Neoplasms 15Breast Neoplasms 15Melanoma 13Thyroid Neoplasms 10Leukemia, Myeloid, Acute 10Sarcoma 9Lung Neoplasms 8Kidney Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 7Urinary Bladder Neoplasms 6Pancreatic Neoplasms 6Glioblastoma 6Brain Neoplasms 6Colorectal Neoplasms 5Carcinoma, Medullary 5Thyroid Carcinoma, Anaplastic 4Stomach Neoplasms 4Rectal Neoplasms 4Gliosarcoma 4Gallbladder Neoplasms 4Colonic Neoplasms 4Breast Neoplasms, Male 4Thyroid Diseases 3Thyroid Cancer, Papillary 3

Interventions

Temozolomide 46Radiotherapy 36Bevacizumab 34Carmustine 13Erlotinib Hydrochloride 11Irinotecan 10sargramostim 7Thalidomide 7Chemotherapy, Adjuvant 7Carboplatin 7Radiation 6pembrolizumab 5Topotecan 5Magnetic Resonance Spectroscopy 5Filgrastim 5Drug Therapy 5Cyclophosphamide 5aldesleukin 4Tamoxifen 4Surgical Procedures, Operative 4Sorafenib 4O(6)-benzylguanine 4Gefitinib 4Etoposide 4Celecoxib 4cediranib 3Radiotherapy, Intensity-Modulated 3Radiotherapy, Conformal 3Peripheral Blood Stem Cell Transplantation 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Gliosarcoma × Sorafenib × Clear all
NCT00621686 2018-05-08

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

Alliance for Clinical Trials in Oncology

Phase 2 Completed
54 enrolled 8 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00445588 2016-04-27

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 6 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT02599090 2015-11-06

Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00597493 2013-06-24

Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

Duke University

Phase 2 Completed
32 enrolled 9 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡